Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.
Status:
Recruiting
Trial end date:
2024-01-06
Target enrollment:
Participant gender:
Summary
Open-label, multi-center, non-randomized, multiple dose, safety, tolerability,
pharmacokinetic, and pharmacodynamics and clinical activity study of PF-06940434 in patients
with SCCHN (Squamous Cell Carcinoma of the Head and Neck), renal cell carcinoma (RCC - clear
cell and papillary), ovarian, gastric, esophageal, esophageal (adeno and squamous), lung
squamous cell, pancreatic and biliary duct, endometrial, melanoma and urothelial tumors. This
study contains two parts, single agent dose escalation (Part 1A), dose finding of PF 06940434
in combination with anti-PD-1 (Part 1B) and dose expansion (Part 2). Part 2 Dose Combination
Expansion will enroll participants into 2 cohorts at doses determined from Part 1B in order
to further evaluate the safety of PF-06940434 in combination with anti-PD-1.